Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New EU Filings

Executive Summary

Ryzneuta, Evive Biotech’s treatment for chemotherapy-induced neutropenia in cancer patients, is among the latest new medicines that have been submitted for review for potential pan-EU approval.

You may also be interested in...



Nine Major Approval Decisions To Watch In Early 2022

Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.

Rare EU Fast-Track Nod For Sanofi Genzyme's Olipudase Alfa

Only three planned marketing authorization applications are known to have been granted accelerated assessment status by the European Medicines Agency between July and October this year. 

First-Of Kind BMS Drugs Among Myriad New Filings In EU

Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.

Topics

Latest News
UsernamePublicRestriction

Register

PS145132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel